Patients with high-risk, advanced-stage melanoma who received the immunotherapy drug pembrolizumab both before surgery (neoadjuvant) and after surgery (adjuvant) had longer event-free survival than patients who received immunotherapy only after surgery according to a recent clinical trial published in the New England Journal of Medicine.
Clinical Trials
Neoantigen Vaccine With Pembrolizumab Has Clear Benefit in Resected Melanoma
Jeffrey S. Weber, MD, PhD, discusses recently released data on a new antigen vaccine with pembrolizumab.
Nivolumab Plus Relatlimab Induces Durable Responses in Advanced Melanoma
The combination of nivolumab (nivolumab) and relatlimab (Opdualag) demonstrated clinical benefit with a manageable safety profile in patients with advanced melanoma who have progressed on prior PD-L1 or PD-1 inhibitors, regardless of PD-L1 and LAG-3 expression, according to findings from the ongoing phase 1/2a RELATIVITY-020 trial (NCT01968109).
Nivolumab Plus Relatlimab Yields Durable Responses After Progression of Advanced Melanoma
Nivolumab plus relatlimab can produce durable responses in patients with advanced melanoma whose disease progressed on anti-PD-1/PD-L1 regimens, according to findings published in the Journal of Clinical Oncology.